56245-67-1
Chemical Structure
(+)-Butaclamol
Synonym(s): (+)-AY-23,028 free base; d-Butaclamol
- CAS No.: 56245-67-1
- Formula:C25H31NO
- Molecular Weight:361.52
InChIKey: ZZJYIKPMDIWRSN-HWBMXIPRSA-N
SMILES: CC(C)([C@]1(C[C@@]2([H])C3=CC=CC4=C3[C@](CN2CC1)([H])C5=CC=CC=C5CC4)O)C
Biological Activity: (+)-Butaclamol ((+)-AY-23,028 free base; d-Butaclamol) is a dopamine receptor antagonist that blocks D2 and D1 receptors. (+)-Butaclamol antagonizes Dopamine (HY-B0451)-induced relaxation with a KB of 2 nM-0.17 µM and a Ki of 0.19-0.37 µM. (+)-Butaclamol inhibits adenylyl cyclase-coupled dopamine receptors, displaces striatal D2 radioligand binding, and acts as a non-selective D2 antagonist to retain D1-NLS and D1-D2 hetero-oligomers on the cell surface. (+)-Butaclamol inhibits the rewarding effects and self-administration behavior of dopaminergic agonists. (+)-Butaclamol can be used in research related to schizophrenia[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(+)-Butaclamol | (+)-Butaclamol ((+)-AY-23,028 free base; d-Butaclamol) is a dopamine receptor antagonist that blocks D2 and D1 receptors. (+)-Butaclamol antagonizes Dopamine (HY-B0451)-induced relaxation with a KB of 2 nM-0.17 µM and a Ki of 0.19-0.37 µM. (+)-Butaclamol inhibits adenylyl cyclase-coupled dopamine receptors, displaces striatal D2 radioligand binding, and acts as a non-selective D2 antagonist to retain D1-NLS and D1-D2 hetero-oligomers on the cell surface. (+)-Butaclamol inhibits the rewarding effects and self-administration behavior of dopaminergic agonists. (+)-Butaclamol can be used in research related to schizophrenia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1(2):133-52.
- [2]. Brodde OE. Vascular dopamine receptors: Demonstration and characterization by in vitro studies. Life Sci. 1982 Jul 26;31(4):289-306.
- [3]. O'Dowd BF, et al. Dopamine receptor oligomerization visualized in living cells. The Journal of biological chemistry. 2005 Nov 04;280(44):37225-35.
- [4]. Miller JC, et al. Development of specificity and stereoselectivity of rat brain dopamine receptors. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 1986;4(1):21-6.
- [5]. Yokel RA, et al. Amphetamine- type reinforcement by dopaminergic agonists in the rat. Psychopharmacology. 1978 Jul 19;58(3):289-96.
